



## EPH and Ephrins in Pathogenesis and as Drug Target

Guest Editors:

### **Dr. Massimiliano Tognolini**

Department of Food and Drug,  
University of Parma, 43124  
Parma, Italy

### **Prof. Dr. Jiangping Wu**

Centre Hospitalier de L'Universite  
de Montreal, University of  
Montreal, Montreal, QC, Canada

### **Dr. Carmine Giorgio**

Department of Food and Drug,  
University of Parma, 43124  
Parma, Italy

Deadline for manuscript  
submissions:

**closed (23 December 2023)**

### **Message from the Guest Editors**

Thirty-five years later the discovery of the first EPH gene by Takaku's group, Eph receptors and the ephrin ligands constitute a complex and redundant cellular communication network.

Nowadays a wide plethora of biological techniques and pharmacological tools are available to investigate the roles and the potential benefits of Eph/ephrin targeting in several diseases. Unfortunately, despite the research efforts, drugs targeting this system have not reached the market yet, and the gap between the bench and the bed still exists.

The present Special Issue of Pharmaceuticals aims to be not only a synthesis of the meeting Eph/ephrin system ([www.ephrins.org](http://www.ephrins.org)) we recently organized, but also an opportunity for all the scientists in this field. This special issue purposes to collect the most updated works and to be a valid source of inspiration for future research in the field of Eph/ephrin targeting.

We sincerely hope that you will be able to submit your original contributions in this Special Issue, that want to be a valuable piece of the state of the art on Eph/ephrin targeting puzzle.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

## Contact Us

*Pharmaceuticals* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceuticals](http://mdpi.com/journal/pharmaceuticals)  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)  
[X@Pharmaceut\\_MDPI](https://twitter.com/Pharmaceut_MDPI)